Advertisement
UK markets closed

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • FTSE 250

    20,120.36
    -75.59 (-0.37%)
     

  • AIM

    776.04
    -4.39 (-0.56%)
     

  • GBP/EUR

    1.1845
    -0.0034 (-0.29%)
     

  • GBP/USD

    1.2686
    -0.0074 (-0.58%)
     

  • Bitcoin GBP

    52,224.86
    -18.11 (-0.03%)
     

  • CMC Crypto 200

    1,374.50
    -43.37 (-3.06%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     
Brands:

How I founded Britain's most respected removals firm

'Doing removals defines you for the rest of your working life'

Is AlzChem Group AG's (ETR:ACT) Latest Stock Performance A Reflection Of Its Financial Health?

editorial-team@simplywallst.com (Simply Wall St)
·3-min read

Most readers would already be aware that AlzChem Group's (ETR:ACT) stock increased significantly by 73% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Specifically, we decided to study AlzChem Group's ROE in this article.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

Check out our latest analysis for AlzChem Group

How Do You Calculate Return On Equity?

The formula for ROE is:

ADVERTISEMENT

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for AlzChem Group is:

22% = €39m ÷ €179m (Based on the trailing twelve months to March 2024).

The 'return' is the income the business earned over the last year. One way to conceptualize this is that for each €1 of shareholders' capital it has, the company made €0.22 in profit.

What Has ROE Got To Do With Earnings Growth?

So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

AlzChem Group's Earnings Growth And 22% ROE

Firstly, we acknowledge that AlzChem Group has a significantly high ROE. Additionally, the company's ROE is higher compared to the industry average of 8.5% which is quite remarkable. Probably as a result of this, AlzChem Group was able to see a decent net income growth of 15% over the last five years.

We then compared AlzChem Group's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 11% in the same 5-year period.

past-earnings-growth
past-earnings-growth

Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. What is ACT worth today? The intrinsic value infographic in our free research report helps visualize whether ACT is currently mispriced by the market.

Is AlzChem Group Using Its Retained Earnings Effectively?

AlzChem Group has a healthy combination of a moderate three-year median payout ratio of 35% (or a retention ratio of 65%) and a respectable amount of growth in earnings as we saw above, meaning that the company has been making efficient use of its profits.

Moreover, AlzChem Group is determined to keep sharing its profits with shareholders which we infer from its long history of six years of paying a dividend. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 33% of its profits over the next three years. Accordingly, forecasts suggest that AlzChem Group's future ROE will be 21% which is again, similar to the current ROE.

Conclusion

Overall, we are quite pleased with AlzChem Group's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.